Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Germany”

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's DiseaseRecruiting
NCT07203001Phase 2Updated Aug 19, 2026
Sponsor: Novartis Pharmaceuticals
Still´s Disease
United States, Canada, France, Germany, Italy +3 more
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerRecruiting
NCT06467357Phase 3Updated Aug 19, 2026
Sponsor: AstraZeneca
Biliary Tract Cancer
United States, Australia, Austria, Belgium, Brazil +22 more
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic ArthritisRecruiting
NCT06869551Phase 3Updated Aug 19, 2026
Sponsor: Bristol-Myers Squibb
Juvenile Psoriatic Arthritis
United States, Brazil, Bulgaria, China, Czechia +6 more
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic UrticariaRecruiting
NCT06865651Phase 2Updated Aug 19, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
United States, France, Germany, Poland, Spain
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaActive Not Recruiting
NCT03007147Phase 3Updated Aug 19, 2026
Sponsor: Children's Oncology Group
Acute Lymphoblastic Leukemia · B Acute Lymphoblastic Leukemia · Mixed Phenotype Acute Leukemia · T Acute Lymphoblastic Leukemia
United States, Australia, Austria, Belgium, Canada +14 more
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseRecruiting
NCT07181109Phase 3Updated Aug 19, 2026
Sponsor: Alnylam Pharmaceuticals
High Risk Cardiovascular Disease · Hypertension · High Cardiovascular Risk
United States, Argentina, Australia, Austria, Belgium +29 more
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaRecruiting
NCT06556563Phase 3Updated Aug 19, 2026
Sponsor: NovoCure GmbH
Glioblastoma
United States, Canada, Czechia, France, Germany +7 more
Prospective Analysis of Blood Flow Restriction Training in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Compared to Conventional Strength TrainingCompleted
NCT07772687NAUpdated Aug 19, 2026
Sponsor: University of Bonn
Rheumatoid Arthritis · Psoriatic Arthritis
Germany
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Recruiting
NCT06937229Phase 3Updated Aug 19, 2026
Sponsor: Bristol-Myers Squibb
Alzheimer Disease · Agitation
United States, Argentina, Brazil, Bulgaria, Canada +21 more
Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation SystemActive Not Recruiting
NCT05501873N/AUpdated Aug 19, 2026
Sponsor: Boston Scientific Corporation
Atrial Fibrillation
Australia, Austria, Belgium, Czechia, Finland +16 more
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1Recruiting
NCT06767514Phase 3Updated Aug 19, 2026
Sponsor: Summit Therapeutics
Non-Small Cell Lung Cancer
United States, Belgium, Canada, China, France +12 more
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental VitiligoRecruiting
NCT07431177Phase 2Updated Aug 19, 2026
Sponsor: Novartis Pharmaceuticals
Non-segmental Vitiligo
United States, Argentina, Australia, Canada, China +7 more
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck CancerActive Not Recruiting
NCT04958239Phase 1Updated Aug 19, 2026
Sponsor: Boehringer Ingelheim
Neoplasms
United States, Australia, Belgium, Brazil, China +10 more
Testing the Protective and Caring Effect of a Water-in-oil Formulation in Patients Suffering From Urinary and/or Fecal Incontinence and Requiring Incontinence Care ProductsCompleted
NCT06924502NAUpdated Aug 19, 2026
Sponsor: Dr. August Wolff GmbH & Co. KG Arzneimittel
Incontinence, Urinary · Incontinence, Fecal
Germany
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaActive Not Recruiting
NCT05100862Phase 3Updated Aug 19, 2026
Sponsor: BeOne Medicines
Relapsed/Refractory Follicular Lymphoma · Marginal Zone Lymphoma
United States, Argentina, Australia, Austria, Belgium +23 more
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisRecruiting
NCT07207811Phase 3Updated Aug 19, 2026
Sponsor: Novo Nordisk A/S
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
United States, Argentina, Australia, Belgium, Brazil +15 more
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)Active Not Recruiting
NCT06087835Phase 3Updated Aug 19, 2026
Sponsor: AstraZeneca
Chronic Kidney Disease With High Proteinuria
United States, Argentina, Australia, Austria, Brazil +25 more
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)Recruiting
NCT06935357Phase 3Updated Aug 19, 2026
Sponsor: Biogen
Immunoglobulin A Nephropathy (IgAN)
United States, Argentina, Australia, Belgium, Brazil +23 more
A Study to Learn About How a New Nurandociguat Tablet is Absorbed and Processed in the Body Compared to an Old Tablet and How Food Affects the Way the New Tablet is Absorbed and Processed in the BodyRecruiting
NCT07722585Phase 1Updated Aug 19, 2026
Sponsor: Bayer
Chronic Kidney Disease
Germany
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without PembrolizumabRecruiting
NCT07486817Phase 2Updated Aug 19, 2026
Sponsor: Boehringer Ingelheim
Lung Cancer, Non-squamous, Non-small Cell
Australia, China, France, Germany, Japan +2 more
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)Completed
NCT03740165Phase 3Updated Aug 19, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
United States, Australia, Belgium, Brazil, Canada +17 more
Non-interventional Study of Patients With Transthyretin (ATTR) AmyloidosisRecruiting
NCT06465810N/AUpdated Aug 19, 2026
Sponsor: AstraZeneca
Transthyretin Amyloidosis · ATTR-CM · ATTRv-PN · ATTR
United States, Canada, China, Germany, Spain +1 more
Evaluation of a Modularized Cognitive Behavioral Group Therapy Programme for Young Adults (CHANGE-Study)Not Yet Recruiting
NCT07772180NAUpdated Aug 19, 2026
Sponsor: Max-Planck-Institute of Psychiatry
Psychiatric Disorder
Germany
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic SclerosisRecruiting
NCT06655896Phase 2Updated Aug 19, 2026
Sponsor: Novartis Pharmaceuticals
Scleroderma, Diffuse
United States, Argentina, Australia, Austria, Belgium +17 more
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque PsoriasisActive Not Recruiting
NCT06425549Phase 3Updated Aug 19, 2026
Sponsor: UCB Biopharma SRL
Moderate to Severe Plaque Psoriasis
United States, Belgium, Canada, Czechia, Germany +5 more

Previous page Next page